The present invention relates to a culture medium, preferably a cell culture medium, comprising at least one dipeptide, the dipeptide comprising asparagine (Asn) and glutamine (Gln). The invention further relates to the use of a culture medium of the invention for culturing cells, preferably plant cells, animal cells or mammalian cells. Another aspect of the invention relates to a method of manufacturing a cell culture product comprising the steps of (i) providing a cell capable of producing said cell culture product; (ii) contacting said cell with a culture medium according to the invention; and (iii) obtaining said cell culture product from said culture medium or from said cell.

The invention relates to a culture medium containing at least one oligopeptide of 2-10 amino acids in length. The amino acids are natural amino acids. At least one of the amino acids is lysine; and one further is cysteine, cystine, leucine, tyrosine, valine, or Isoleucine. The oligopeptide is present in an amount of at least 0.1 mM. The invention also relates to the use of the culture medium for culturing cells, preferably plant cells, animal cells or mammalian cells. The invention further relates to a method of manufacturing a cell culture product including the steps of (i) providing a cell capable of producing the cell culture product; (ii) contacting the cell with the culture medium, and (iii) obtaining the cell culture product from the culture medium or from the cell.

Disclosed herein include methods, compositions and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells such as pluripotent embryonic stem cells. In some embodiments, the method can comprise co-culturing a wild-type mammalian pluripotent stem cell and modified mammalian pluripotent stem cells comprising one or more genes encoding transcription factors that can drive generation of extraembryonic cells or extraembryonic-like cells (e.g., GATA6 gene, SOX17 gene, GATA3 gene and/or TFAP2C gene) under a condition in a culture medium allowing the pluripotent stem cells to self-organize into a post-implantation embryo structure. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells and the generated synthetic embryo is a human embryo.

The present invention provides for methods of differentiating induced pluripotent stem cells into pancreatic progenitor cells, pancreatic ductal cells, pancreatic endocrine cells, pancreatic acinar cells, and pancreatic organoids. Cells created by these methods are also provided. Further provided are disease models and methods of drug screening.

Described herein is a low perfusion rate cell culture method for producing recombinant proteins.

The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

This invention relates, inter alia, to compositions of low serum or serum free media and methods for the expansion of T cell populations and methods for using such populations of cells. In some aspects, the invention relates to compositions and methods for the selective expansion of T cell subpopulations.

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.